178 related articles for article (PubMed ID: 34572958)
81. Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma.
Pantalone MR; Rahbar A; Söderberg-Naucler C; Stragliotto G
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454863
[TBL] [Abstract][Full Text] [Related]
82. Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes.
Gaudino S; Marziali G; Giordano C; Gigli R; Varcasia G; Magnani F; Chiesa S; Balducci M; Costantini AM; Della Pepa GM; Olivi A; Russo R; Colosimo C
Front Radiol; 2021; 1():790456. PubMed ID: 37492166
[TBL] [Abstract][Full Text] [Related]
83. Effects of Reoperation Timing on Survival among Recurrent Glioblastoma Patients: A Retrospective Multicentric Descriptive Study.
Kalita O; Kazda T; Reguli S; Jancalek R; Fadrus P; Slachta M; Pospisil P; Krska L; Vrbkova J; Hrabalek L; Smrcka M; Lipina R
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173996
[TBL] [Abstract][Full Text] [Related]
84. Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review.
Gatto L; Franceschi E; Tosoni A; Di Nunno V; Maggio I; Tonon C; Lodi R; Agati R; Bartolini S; Brandes AA
Clin Case Rep; 2021 Aug; 9(8):e04604. PubMed ID: 34457284
[TBL] [Abstract][Full Text] [Related]
85. Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era.
Leone A; Colamaria A; Fochi NP; Sacco M; Landriscina M; Parbonetti G; de Notaris M; Coppola G; De Santis E; Giordano G; Carbone F
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009473
[TBL] [Abstract][Full Text] [Related]
86. Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects.
Pineda E; Domenech M; Hernández A; Comas S; Balaña C
Onco Targets Ther; 2023; 16():71-86. PubMed ID: 36721854
[TBL] [Abstract][Full Text] [Related]
87. Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation.
Fougner V; Hasselbalch B; Lassen U; Weischenfeldt J; Poulsen HS; Urup T
Neurooncol Adv; 2022; 4(1):vdac157. PubMed ID: 36325372
[TBL] [Abstract][Full Text] [Related]
88. Therapeutic efficacy of
Khoshnevis M; Brown R; Belluco S; Zahi I; Maciocco L; Bonnefont-Rebeix C; Pillet-Michelland E; Tranel J; Roger T; Nennig C; Oudoire P; Marcon L; Tillement O; Louis C; Gehan H; Bardiès M; Mariani M; Muzio V; Meunier JP; Duchemin C; Michel N; N'Tsiba E; Haddad F; Buronfosse T; Carozzo C; Ponce F
Front Oncol; 2022; 12():923679. PubMed ID: 36419904
[TBL] [Abstract][Full Text] [Related]
89. Editorial for "Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells".
Kolothara Unnikrishnan M; Schmidt MHH
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568645
[TBL] [Abstract][Full Text] [Related]
90. Erratum: Regorafenib in Patients With Solid Tumors With
JCO Precis Oncol; 2024 Apr; 8():e2400121. PubMed ID: 38603653
[No Abstract] [Full Text] [Related]
91. Relapsed glioblastomas respond to regorafenib.
Sidaway P
Nat Rev Clin Oncol; 2019 Mar; 16(3):144. PubMed ID: 30573791
[No Abstract] [Full Text] [Related]
92. Is the "unresected" glioblastoma population a real specific entity?
Dhermain F
Neurooncol Pract; 2023 Dec; 10(6):502-503. PubMed ID: 38009117
[No Abstract] [Full Text] [Related]
93. Clinical activity of regorafenib in elderly patients with recurrent glioblastoma.
Fasano M; Pirozzi M; Famiglietti V; Facchini S; Caterino M; Caroprese M; Barillaro A; Di Giovanni I; Auriemma A; Ileana Sara Fattoruso S; Somma T; Solari D; Bocchetti M; Conson M; Pacelli R; Ciardiello F; Addeo R
Mol Clin Oncol; 2023 Feb; 18(2):9. PubMed ID: 36761386
[TBL] [Abstract][Full Text] [Related]
94. Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?
Rudà R; Bruno F; Pellerino A; Pronello E; Palmiero R; Bertero L; Crasto S; Polo V; Vitaliani R; Trincia E; Internò V; Porta C; Soffietti R
J Neurooncol; 2022 Nov; 160(2):389-402. PubMed ID: 36309895
[TBL] [Abstract][Full Text] [Related]
95. Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma.
Chiesa S; Mangraviti A; Martini M; Cenci T; Mazzarella C; Gaudino S; Bracci S; Martino A; Della Pepa GM; Offi M; Gessi M; Russo R; Martucci M; Beghella Bartoli F; Larocca LM; Lauretti L; Olivi A; Pallini R; Balducci M; D'Alessandris QG
Sci Rep; 2022 Sep; 12(1):16265. PubMed ID: 36171338
[TBL] [Abstract][Full Text] [Related]
96. New Directions in the Therapy of Glioblastoma.
Szklener K; Mazurek M; Wieteska M; Wacławska M; Bilski M; Mańdziuk S
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358795
[TBL] [Abstract][Full Text] [Related]
97. Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity.
Treiber H; von der Brelie C; Malinova V; Mielke D; Rohde V; Chapuy CI
Neurosurg Rev; 2022 Oct; 45(5):3201-3208. PubMed ID: 35725846
[TBL] [Abstract][Full Text] [Related]
98. Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study.
Aoki T; Kagawa N; Sugiyama K; Wakabayashi T; Arakawa Y; Yamaguchi S; Tanaka S; Ishikawa E; Muragaki Y; Nagane M; Nakada M; Suehiro S; Hata N; Kuroda J; Narita Y; Sonoda Y; Iwadate Y; Natsumeda M; Nakazato Y; Minami H; Hirata Y; Hagihara S; Nishikawa R
Int J Clin Oncol; 2021 Dec; 26(12):2205-2215. PubMed ID: 34586548
[TBL] [Abstract][Full Text] [Related]
99. The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma.
Ahmadov U; Picard D; Bartl J; Silginer M; Trajkovic-Arsic M; Qin N; Blümel L; Wolter M; Lim JKM; Pauck D; Winkelkotte AM; Melcher M; Langini M; Marquardt V; Sander F; Stefanski A; Steltgens S; Hassiepen C; Kaufhold A; Meyer FD; Seibt A; Kleinesudeik L; Hain A; Münk C; Knobbe-Thomsen CB; Schramm A; Fischer U; Leprivier G; Stühler K; Fulda S; Siveke JT; Distelmaier F; Borkhardt A; Weller M; Roth P; Reifenberger G; Remke M
Cell Death Dis; 2021 Sep; 12(10):885. PubMed ID: 34584066
[TBL] [Abstract][Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
